Who Decides What a Medical Breakthrough Is Actually Worth?

What is the exact dollar value of staying awake? In this special episode, we dig into a real independent evidence report on Orzeyful (oporexin), a newly FDA-approved drug for narcolepsy type 1 that works completely differently from anything currently on the market — it doesn't just manage symptoms, it replaces the missing brain chemical behind the disease itself.

We break down what the science actually means, why a "C++" grade from independent researchers is secretly a huge win, why the $50,000-a-year price tag might actually be the fair one, and the insurance practice called step therapy that could still stand between patients and the drug they need.

About The Episode 

This is a special deep-dive episode: instead of a guest conversation, we're unpacking a real independent evidence report — from the Institute for Clinical and Economic Review (ICER), based on an August 2026 Sleep Review article — on Orzeyful, a newly approved narcolepsy type 1 treatment, and what its pricing debate means for patient access.

Resources: 

•  Institute Publishes Evidence Report on New Narcolepsy Treatment (Sleep Review) 
•   ICER Final Evidence Report: Overporexton for Narcolepsy Type 1
• Evidence Rating Details: B+ and C++ Explained (ICER) 
• Policy Recommendations on Pricing and Access (ICER)
• FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms (FDA)
• FDA Approves Takeda's Orexin Agonist for NT1: Orzeyful (Sleep Review)